| Document |
Document Title |
|
WO/2013/074798 |
The present invention provides apoaequorin-based compositions and methods for preconditioning neurons in a subject to reduce neuronal injury due to brain ischemia. Methods include the step of administering apoaequorin to neurons in a sub...
|
|
WO/2013/071440 |
Methods and products (e.g., recombinant proteins) are described for increasing frataxin expression/levels in a cell, as well as uses of such methods and products, for example for the treatment of Friedreich ataxia in a subject suffering ...
|
|
WO/2013/072328 |
Use of Telaprevir and related compounds in atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases The present invention relates to a compound of the formula I for use in the treatment of atherosclerosis, ...
|
|
WO/2013/072062 |
It has been found that phenyl carbamates, in particular Rivastigmine, can be formulated as a stable TTS by using a monolayer poly alkyl (meth)acrylates, wherein the poly alkyl (meth)acrylates are substantially free of free carboxylate gr...
|
|
WO/2013/071715 |
The present invention includes histone deacetylase inhibitors represented by formula I, wherein R1 to R8 are defined in the specification. The present invention also comprises s the synthetic method of the compounds, and the use of the c...
|
|
WO/2013/072705 |
This invention relates to compounds that are agonists of the muscarinic M1 receptor and which are useful in the treatment of muscarinic M1 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds...
|
|
WO/2013/074986 |
The present invention provides novel compounds according to Formula (I): where Ring A, Ring B, X, L1, L2, RA, RC, RD, RE, m, n, and p are as defined herein. Compounds of the present invention are contemplated useful for the prevention an...
|
|
WO/2013/072520 |
The present invention relates to N-substituted aminobenzocycloheptene,aminotetraline, aminoindane and phenalkylamine derivatives of the formula (I),(II), (III) or (IV) or a physiologically tolerated salt thereof. The invention relates to...
|
|
WO/2013/072758 |
The present disclosure provides pyrimidine diol amides of Formula (I), and the pharmaceutically acceptable solvates and prodrugs thereof, wherein A1, X, A2, W1, W2, W3, R1, R2, and R4 are defined as set forth in the specification. The pr...
|
|
WO/2013/073577 |
[Problem] To provide a compound which has a D-amino acid oxidase (DAAO) inhibitory effect and is useful, for example, as a prophylactic and/or therapeutic agent for schizophrenia and neuropathic pain. [Solution] The inventors have achiev...
|
|
WO/2013/071421 |
Orally administrable modified release pharmaceutical composition comprising pellets which comprise: (a) an inert core: (b) a first layer comprising a therapeutic agent, such as an amphetamine, and a hydrophilic binder: and (c) a modified...
|
|
WO/2013/071418 |
A method for preparing plasmalogens and derivatives thereof represented by Formula B, wherein R1 and R2 are similar or different, derived from fatty acids; R3 is selected from hydrogen and small alkyl groups. The synthetic route involves...
|
|
WO/2013/071061 |
Compositions and methods for increasing resilience to the effects of stress are provided. Methods inhibit, treat, and/or prevent a stress- related disorder or symptoms thereof are provided. The method comprises increasing sphingosine-1 -...
|
|
WO/2013/067591 |
The present disclosure relates generally to the field of pain management, including methods and formulations for the topical management of pain, such as localized pain. The present disclosure further teaches combination therapy to topica...
|
|
WO/2013/069339 |
Provided is a puncture pain alleviating external preparation which causes little pain and which can be easily used. The puncture pain alleviating external preparation of the present invention is to be applied in the vicinity of the site ...
|
|
WO/2013/070961 |
Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette ("ABC") transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regu...
|
|
WO/2013/071267 |
The present disclosure provides for a hyperimmune preparation comprising human polyclonal antibodies or fragments thereof specific to a cyclic peptide having an amino acid sequence comprising SNK. The cyclic peptide may comprise an amino...
|
|
WO/2013/070236 |
The present invention relates to compositions and methods for treatment of internal and/or external hemorrhoids, wherein the treatment includes topically administering to a subject a composition comprising from 0.3% to 0.7% of S-2'- [2-(...
|
|
WO/2013/069861 |
The present invention relates to a pharmaceutical composition for preventing and treating neuropathic pain containing GABA nerve cells differentiated and induced by treating adipose tissue-derived stem cells with CBM-1078 as an active in...
|
|
WO/2013/068330 |
The present invention is concerned with plant derived pharmaceutically useful compositions. In particular, it relates to a composition for use in treating and/or preventing a neurodegenerative disorder or disease, wherein said compositio...
|
|
WO/2013/068504 |
The present invention relates to the use of apotransferrin for the preparation of a medicament for the treatment of brain stroke. Particularly the invention relates to the use of apotransferrin for the preparation of a medicament for the...
|
|
WO/2013/070879 |
The invention is directed to methods for treating spinal cord injury and other neurological conditions by administering an LPA1 receptor antagonist or an autotaxin inhibiting compound.
|
|
WO/2013/068470 |
The present invention relates to novel compounds of the formula (I) which are inhibitors of phosphodiesterase type 10A and to their use for the manufacture of a medicament and which thus are suitable for treating or controlling of medica...
|
|
WO/2013/068935 |
The present invention relates to 2-(1,2,3-triazol-2-yl)benzamide and 3-(1,2,3-triazol-2- yl)picolinamide derivatives of formula (I) Formula (I) wherein Ar1, Q, and R1 to R5 are as described in the description, to their preparation, to ph...
|
|
WO/2013/070011 |
Disclosed are a method or composition for the prevention or treatment of a neurological disease, comprising an AMPA endocytosis inhibitor. The present invention is useful as an agent for the prevention or treatment of various neurologica...
|
|
WO/2013/068431 |
The present application provides a method for treating a neurodegenerative disease in a subject characterised in that the endoplasmic reticulum protein retrotranslocation machinery and/or VCP is modulated by administering to said subject...
|
|
WO/2013/067770 |
The invention provides a method for inhibiting damage to a neural cell following traumatic brain injury. The method comprises the step of exposing at least one neural cell to an effective amount of pharmaceutical agent that inhibits N-me...
|
|
WO/2013/071281 |
The present disclosure relates to esters of 8-[2-(2-pentyl- cyclopropylmethyl)cyclopropyl]-octanoic acid ("DCPLA"). The disclosure further relates to compositions, kits, and methods for treatment using the esters.
|
|
WO/2013/068785 |
The invention relates to indanone/indandione derivatives and heterocyclic analogs of Formula (I) wherein Ar1, A, B, L1, Y, Z, and (R1)n n are as described in the description; to pharmaceutically acceptable salts thereof, and to the use o...
|
|
WO/2013/067612 |
The present invention relates to the development of a pharmaceutical composition characterized by comprising triancinolone, bupivacaine and ethanol in the form of a suspension, the use thereof characterized by being for the preparation o...
|
|
WO/2013/067710 |
Disclosed are compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed.
|
|
WO/2013/070821 |
Disclosed herein are compositions and methods of use thereof for treating diseases, disorders and injuries of the nervous system, com¬ prising a combination of a RTP801 or RTP801L inhibitor, and a Casp2 inhibitor.
|
|
WO/2013/070107 |
The invention relates to the field of pharmacology and medicine and concerns compounds which can be useful as antipsychotic agents. The compounds described are 5H-dibenzo[b,e][1,4]diazepine derivatives of general formula (1) or pharmacol...
|
|
WO/2013/071282 |
The present disclosure relates to PKC activators and combinations thereof. The disclosure further relates to compositions, kits, uses, and methods thereof.
|
|
WO/2013/071077 |
A method of prevention and treatment for a neurodegenerative disease with a pan- PPAR agonist, such as bezafibrate. In particular, the present invention provides that pan- PPAR agonists enhance PPAR related responses in both the central ...
|
|
WO/2013/068592 |
The invention is directed to inhibitors of cystathionine beta synthase which, among other biochemical effects, allow reduction of the neurotoxic overproduction of endogenous hydrogen sulphide. These compounds and pharmaceutical compositi...
|
|
WO/2013/068489 |
Novel inhibitor compounds of phosphodiesterase type 10A The present invention relates to compounds which are inhibitors of phosphodiesterase type 10A and to their use for the manufacture of a medicament and which thus are suitable for tr...
|
|
WO/2013/069765 |
Provided are: a nitrogenated heterocyclic compound represented by formula (I-A)(wherein R1A represents a lower alkyl group which may be substituted by a lower alkoxy group; R3A represents a fluorine-substituted lower alkyl group; and R4A...
|
|
WO/2013/066151 |
The invention relates to a composition for use in the treatment or prevention of recognition dysfunction, and/or for improving recognition, in a (prodromal) Alzheimer's patient, in particular in a drug-naive (prodromal) Alzheimer's patie...
|
|
WO/2013/065224 |
The present invention addresses the problem of providing a non-alcoholic beverage, which shows an excellent cool and refreshing taste and can be obtained by a simple and cost-saving method, and, from the view point of health promotion, w...
|
|
WO/2013/067157 |
The present invention relates to methods and compositions for modulating levels of amyloid-β peptide (Aβ) exhibited by non-neuronal (i.e., peripheral) cells, fluids, or tissues. The invention also relates to modulation of Aβ levels vi...
|
|
WO/2013/067483 |
A delivery system for administration to a patient of Fenobam, its hydrates, and salts optimizes solubility and dissolution properties of Fenobam, its hydrates, and salts using either microemulsions, solid dispersions, cyclodextrin, gastr...
|
|
WO/2013/064445 |
The present invention relates to the use of novel compounds of formula (I): wherein all variable substituents are defined as described herein, which are SYK inhibitors and are useful for the treatment of auto-immune and inflammatory dise...
|
|
WO/2013/064883 |
The invention relates to aryl substituted compounds of Formula (I) : and pharmaceutically acceptable salts, prodrugs, or solvates thereof, wherein Het, G, A, R, and n are defined as set forth in the specification. The invention is also d...
|
|
WO/2013/066152 |
The invention relates to a composition comprising:(i) one or more of uridine and cytidine, or salts, phosphates, acyl derivatives or esters thereof; and (ii) a lipid fraction comprising at least one of docosahexaenoic acid (22:6; DHA), e...
|
|
WO/2013/066153 |
The invention relates to a composition comprising:(i) one or more of uridine and cytidine, or salts, phosphates, acyl derivatives or esters thereof; and (ii) a lipid fraction comprising at least one of docosahexaenoic acid (22:6; DHA), e...
|
|
WO/2013/064029 |
Provided in the present invention are a benzoylurea derivative of formula (I) with anticancer activity or the pharmaceutically acceptable salt or prodrug thereof, and the preparation of such a derivative and the use thereof in preparing ...
|
|
WO/2013/066165 |
The invention relates to a composition for use in the treatment or prevention of recognition dysfunction, and/or for improving recognition, in a (prodromal) Alzheimer's patient, in particular in a drug-naive (prodromal) Alzheimer's patie...
|
|
WO/2013/064031 |
Disclosed are an N-benzylaniline derivative and uses thereof. The derivative is a compound represented by formula I or a pharmaceutically acceptable salt thereof. The compound has an action of protecting against cerebral ischemia/reperfu...
|
|
WO/2013/067415 |
Described herein are compositions and methods for treating sickle cell disease and methods for identifying agents to treat or prevent sickle cell disease.
|
